Biotech | August 30, 2021
Vivo Bio Tech enters long-term contract with Bio E
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The segment delivered strong sales growth of 20% YoY
The centre established by Nucleome Informatics will take up the sequencing of 5,000 Covid genomes and 500 human genomes in the coming months
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
Subscribe To Our Newsletter & Stay Updated
